Acumen Pharmaceuticals, Inc.
ABOS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $22 | $37 | $25 | $35 |
| G&A Expenses | $0 | $5 | $5 | $5 |
| SG&A Expenses | $5 | $5 | $5 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $27 | $42 | $30 | $40 |
| Operating Income | -$27 | -$42 | -$30 | -$40 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $1 | $2 | $2 |
| Pre-Tax Income | -$26 | -$41 | -$29 | -$37 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$26 | -$41 | -$29 | -$37 |
| % Margin | – | – | – | – |
| EPS | -0.44 | -0.68 | -0.48 | -0.62 |
| % Growth | 35.3% | -41.7% | 22.6% | – |
| EPS Diluted | -0.44 | -0.68 | -0.48 | -0.62 |
| Weighted Avg Shares Out | 61 | 61 | 61 | 60 |
| Weighted Avg Shares Out Dil | 61 | 61 | 61 | 60 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $2 | $3 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$25 | -$40 | -$28 | -$36 |
| % Margin | – | – | – | – |